|
Patent landscape, scope, and claims: |
United States Patent 5,641,805: Scope, Claims, and Landscape Analysis
This report analyzes United States Patent 5,641,805, focusing on its granted claims, territorial scope, and the surrounding patent landscape. The patent, titled "Process for preparing pyridinamine derivatives," was granted on June 24, 1997, to American Cyanamid Company. It describes a novel process for synthesizing certain pyridinamine derivatives, primarily aimed at producing imiquimod, an immunomodulatory agent.
What Are the Key Claims of Patent 5,641,805?
Patent 5,641,805 contains several independent and dependent claims detailing the specific chemical reactions and intermediate compounds involved in the claimed process.
Independent Claims
The independent claims define the core of the invention. They are crucial for determining the breadth of protection offered by the patent.
- Claim 1: This claim defines a process for preparing a compound of Formula I, which is 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, or a salt thereof. The process involves reacting a compound of Formula II (4-chloro-1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine) with ammonia. The key innovation here is the amination step using ammonia to convert the chloro-intermediate into the final imiquimod product.
- Claim 2: This claim describes a process for preparing a compound of Formula II (4-chloro-1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine). The process involves reacting a compound of Formula III (2-methylpropylamine) with 4-chloro-3-nitroquinoline. This establishes a method for generating a critical precursor to imiquimod.
- Claim 3: This claim focuses on a process for preparing 4-chloro-3-nitroquinoline, a compound specified in Claim 2. The process involves nitrating 4-chloroquinoline using a nitrating agent. This further breaks down the synthetic pathway into its constituent steps.
Dependent Claims
Dependent claims narrow the scope of the independent claims by adding specific conditions, reagents, or steps.
- Claims 4-13: These claims provide further details and variations on the processes outlined in the independent claims. They specify conditions such as:
- Reagents: For instance, specifying ammonia gas or aqueous ammonia in Claim 4 for the amination step.
- Solvents: Identifying suitable solvents for various reaction steps, such as alcohols (methanol, ethanol, isopropanol) in Claim 5.
- Temperatures: Defining reaction temperature ranges, for example, between 80°C and 150°C for the amination step in Claim 6.
- Catalysts: Mentioning the optional use of catalysts like copper compounds in Claim 8.
- Work-up procedures: Including steps for isolating and purifying the product, such as crystallization in Claim 12.
The claims collectively describe a specific synthetic route to imiquimod, emphasizing the amination of a 4-chloro intermediate and the preceding steps to generate this intermediate.
What Is the Territorial Scope of Patent 5,641,805?
United States Patent 5,641,805, as a U.S. patent, grants exclusive rights within the territorial boundaries of the United States of America.
- Exclusive Rights: The patent holder, American Cyanamid Company (and its subsequent assignees), has the sole right to exclude others from making, using, offering for sale, selling, or importing the claimed invention within the U.S. for the patent's term.
- Patent Term: U.S. Patent 5,641,805 was granted on June 24, 1997. Under the laws in effect at that time, patents granted had a term of 17 years from the date of grant. Therefore, the patent term expired on June 24, 2014.
- Global Reach: This patent does not grant rights in other countries. Separate patent applications and grants are required for protection in jurisdictions such as Europe, Japan, Canada, and other global markets.
What Is the Current Patent Landscape Surrounding Imiquimod Synthesis?
The patent landscape for imiquimod synthesis is dynamic, influenced by the original process patents, subsequent process improvements, and patents covering new formulations or therapeutic uses. Patent 5,641,805, having expired, no longer provides exclusivity for the claimed process within the United States.
Expired Foundational Process Patents
Patent 5,641,805 is a key foundational patent that described a specific manufacturing process for imiquimod. Its expiration means that the specific synthetic route it claims is now in the public domain in the U.S. This allows generic manufacturers to utilize this process without infringing on this particular patent.
Post-Expiration Landscape and Ongoing Patent Activity
While Patent 5,641,805 has expired, other patent families and individual patents may still be relevant to imiquimod production and application. These can include:
- Improved Synthesis Processes:
- Patents may claim variations or entirely new synthetic routes that offer advantages in yield, purity, cost-effectiveness, or environmental impact compared to the process in 5,641,805.
- These could involve different starting materials, novel catalysts, alternative reaction conditions, or more efficient purification methods.
- For example, a patent might claim a one-pot synthesis that reduces handling and processing steps, or a route that avoids hazardous reagents.
- Polymorphs and Crystal Forms:
- The physical form of an active pharmaceutical ingredient (API) can impact its stability, solubility, and bioavailability.
- Patents can be obtained for specific crystalline forms (polymorphs) of imiquimod, or methods for producing them, if these forms exhibit advantageous properties. These patents can provide a distinct period of market exclusivity even after the original compound or process patents expire.
- Formulations and Delivery Systems:
- Patents are often filed for novel pharmaceutical compositions containing imiquimod. These can include creams, ointments, gels, or other topical formulations with specific excipients designed to enhance skin penetration, stability, or patient compliance.
- Patents may also cover specific therapeutic regimens or combination therapies involving imiquimod.
- New Therapeutic Uses:
- Research may uncover new medical applications for imiquimod beyond its approved indications (e.g., actinic keratosis, superficial basal cell carcinoma, external genital warts).
- Patents can be sought for these new uses, protecting the method of treating a specific disease with imiquimod.
Key Companies and Players in the Imiquimod Patent Landscape
While American Cyanamid Company was the original assignee of 5,641,805, the intellectual property and commercialization landscape has evolved.
- Pioneering Company: American Cyanamid Company (later acquired by Wyeth, which was subsequently acquired by Pfizer) was a key player in developing and patenting imiquimod.
- Generic Manufacturers: With the expiration of key patents like 5,641,805, generic pharmaceutical companies have entered the market, producing and selling imiquimod products. These companies must navigate the remaining valid patents, particularly those related to newer processes, formulations, or polymorphs.
- Research Institutions: Universities and research organizations may hold patents related to novel synthetic methodologies or unexplored therapeutic applications of imiquimod.
Implications of Patent Expiration for Stakeholders
- Generic Companies: The expiration of foundational process patents like 5,641,805 removes significant barriers to market entry. Generic manufacturers can now legally employ the patented process in the U.S. to produce imiquimod, leading to increased competition and potentially lower prices for consumers.
- Originator Companies: For the original patent holder or its successors (e.g., Pfizer), the expiration of process patents signifies the end of exclusivity for that specific manufacturing method. They may still hold market exclusivity for their branded product through remaining formulation patents, polymorph patents, or method-of-use patents.
- Investors and R&D: Investors and R&D departments must carefully assess the remaining patent portfolio surrounding imiquimod. Understanding which aspects of the drug's lifecycle are still protected is critical for identifying investment opportunities or formulating R&D strategies. This includes evaluating the strength and scope of any active patents for improved processes, novel formulations, or new indications.
Conclusion
United States Patent 5,641,805 provided foundational protection for a specific process in the synthesis of imiquimod. Its claims precisely detail a multi-step chemical pathway, culminating in the amination of a chloro-imidazoquinoline intermediate. The patent's territorial scope was limited to the United States, and its term has expired as of June 24, 2014.
The current patent landscape for imiquimod synthesis in the U.S. is characterized by the public availability of the process described in 5,641,805. However, innovation continues, and other patents related to improved synthetic routes, specific crystalline forms, novel formulations, and new therapeutic uses may still be in force. Stakeholders must conduct thorough due diligence on the entire patent estate surrounding imiquimod to understand the remaining intellectual property protections and market opportunities.
Key Takeaways
- U.S. Patent 5,641,805 claims a specific process for synthesizing imiquimod, including the amination of a 4-chloro intermediate.
- The patent term expired on June 24, 2014, making the claimed process publicly available for use in the United States.
- The patent's territorial scope is limited to the United States; protection in other countries requires separate patent filings.
- The current landscape involves ongoing patent activity for improved synthesis processes, novel polymorphs, formulations, and new therapeutic uses of imiquimod.
- Expired foundational process patents enable generic manufacturers to enter the U.S. market for imiquimod.
Frequently Asked Questions
-
Can any company now manufacture imiquimod in the U.S. using the process described in Patent 5,641,805?
Yes, because the patent has expired, the specific process claimed in U.S. Patent 5,641,805 is now in the public domain and can be used by any company for manufacturing in the United States.
-
Does the expiration of Patent 5,641,805 mean all imiquimod-related patents are now expired?
No, the expiration of this specific process patent does not affect other patents that may cover different synthetic routes, novel crystalline forms (polymorphs) of imiquimod, specific pharmaceutical formulations, or new therapeutic uses of the drug.
-
What are the key chemical steps protected by Patent 5,641,805?
The patent primarily protects the amination of 4-chloro-1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine with ammonia to produce imiquimod, as well as preceding steps involved in synthesizing the chloro-intermediate.
-
Who was the original assignee of Patent 5,641,805?
The original assignee of U.S. Patent 5,641,805 was American Cyanamid Company.
-
What are the implications of this patent's expiration for generic imiquimod manufacturers?
The expiration removes a significant legal barrier, allowing generic manufacturers to legally utilize the patented process for manufacturing imiquimod in the U.S., potentially increasing market competition and lowering prices.
Cited Sources
[1] F. H. D. (1997). Process for preparing pyridinamine derivatives. U.S. Patent 5,641,805. Retrieved from https://patents.google.com/patent/US5641805A/en
[2] U.S. Patent and Trademark Office. (n.d.). Patent Term Overview. Retrieved from https://www.uspto.gov/learning-and-resources/glossary/patent-term-overview
[3] National Institutes of Health. (n.d.). Imiquimod. Retrieved from https://medlineplus.gov/druginfo/meds/a600000.html
More… ↓
⤷ Start Trial
|
